Morniflumate
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328601

CAS#: 65847-85-0

Description: Morniflumate, also known as UP-164 and Morniflu, is a nonsteroidal antiinflammatory drug (NSAID) used to treat inflammation.


Price and Availability

Size Price Shipping out time Quantity
5mg USD 230 2 Weeks
10mg USD 375 2 Weeks
25mg USD 600 2 Weeks
50mg USD 975 2 Weeks
100mg USD 1275 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-30. Prices are subject to change without notice.

Morniflumate (UP-164, Morniflu) is currently on back order. This product will ship about 2 weeks after an order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 328601
Name: Morniflumate
CAS#: 65847-85-0
Chemical Formula: C19H20F3N3O3
Exact Mass: 395.1457
Molecular Weight: 395.3822
Elemental Analysis: C, 57.72; H, 5.10; F, 14.42; N, 10.63; O, 12.14


Synonym: Morniflumate; UP-164; UP 164; UP164; Morniflu; Niflam

IUPAC/Chemical Name: 2-morpholinoethyl 2-((3-(trifluoromethyl)phenyl)amino)nicotinate

InChi Key: LDXSPUSKBDTEKA-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H20F3N3O3/c20-19(21,22)14-3-1-4-15(13-14)24-17-16(5-2-6-23-17)18(26)28-12-9-25-7-10-27-11-8-25/h1-6,13H,7-12H2,(H,23,24)

SMILES Code: O=C(OCCN1CCOCC1)C2=C(NC3=CC=CC(C(F)(F)F)=C3)N=CC=C2


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Cremonesi G, Cavalieri L. Efficacy and safety of morniflumate for the treatment of symptoms associated with soft tissue inflammation. J Int Med Res. 2015 Jun;43(3):290-302. doi: 10.1177/0300060514567212. Epub 2015 Apr 28. Review. PubMed PMID: 25921871.

2: Cho HY, Park GK, Lee YB. Simultaneous determination of morniflumate and its major active metabolite, niflumic acid, in human plasma by high-performance liquid chromatography in stability and pharmacokinetic studies. Biomed Chromatogr. 2013 Nov;27(11):1438-43. doi: 10.1002/bmc.2940. Epub 2013 May 30. PubMed PMID: 23722315.

3: Mero F, Nettis E, Aloia AM, Di Leo E, Ferrannini A, Vacca A. Short-term tolerability of morniflumate in patients with cutaneous hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):247-50. PubMed PMID: 23527729.

4: Civelli M, Vigano T, Acerbi D, Caruso P, Giossi M, Bongrani S, Folco GC. Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9. PubMed PMID: 1659152.

5: Manach Y, Ditisheim A. Double-blind, placebo-controlled multicentre trial of the efficacy and tolerance of morniflumate suppositories in the treatment of tonsillitis in children. J Int Med Res. 1990 Jan-Feb;18(1):30-6. Erratum in: J Int Med Res 1990 Mar-Apr;18(2):preceding 75. PubMed PMID: 2110537.

6: Marchioni CF, Livi E, Oliani C, Guerzoni P, Corona M. [Treatment of acute inflammatory pathology of the upper airway with morniflumate]. Riv Eur Sci Med Farmacol. 1990 Dec;12(6):347-57. Italian. PubMed PMID: 2132289.

7: Schiantarelli P, Cadel S, Folco GC. Gastroprotective effects of morniflumate, an esterified anti-inflammatory drug. Arzneimittelforschung. 1984;34(8):885-90. PubMed PMID: 6333880.

8: Melica A, Donateo L, Gerardi R, Parenti M. [A new anti-inflammatory-analgesic-antipyretic, morniflumate, in the treatment of chronic recurring bronchitis]. Riv Eur Sci Med Farmacol. 1991 Feb-Apr;13(1-2):51-60. Italian. PubMed PMID: 1796197.

9: Schiantarelli P, Cadel S, Acerbi D. A gastroprotective anti-inflammatory agent: the beta-morpholinoethyl ester of niflumic acid (morniflumate). Agents Actions. 1984 Feb;14(2):247-56. PubMed PMID: 6608862.

10: Portmann M, Portmann D, Rohou S, Pollet M, Colson J, Cuvelier A, Fournier JL, Jeannerot F, Marx J, Menet V. [Efficacy and tolerability of morniflumate in acute otitis in infants: results of a randomized study versus placebos]. Rev Laryngol Otol Rhinol (Bord). 1990;111(5):507-10. French. PubMed PMID: 2087618.